Human CellExp™ TROP-2 / TACSTD2, Human recombinant
TACSTD2, GA733-1, M1S1, TROP2
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P09758 |
---|---|
Calculated MW | 28.7 kDa |
Gene ID | 4070 |
---|---|
Other Names | TACSTD2, GA733-1, M1S1, TROP2 |
Gene Source | Human |
Source | HEK 293 cells |
Assay&Purity | SDS-PAGE;> 95% |
Recombinant | Yes |
Target/Specificity | TACSTD2 |
Application Notes | Reconstitute in sterile deionized water to the desired protein concentration. |
Format | Lyophilized |
Storage | -20°C;Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Tumor-associated calcium signal transducer 2 (TACSTD2) is also known as Cell surface glycoprotein Trop-2, Membrane component chromosome 1 surface marker 1 (M1S1), Pancreatic carcinoma marker protein GA733-1, which belongs to the EPCAM family. TACSTD2 contains one thyroglobulin type-1 domain. TACSTD2 is a carcinoma-associated antigen defined by the monoclonal antibody GA733. TACSTD2 transduces an intracellular calcium signal and acts as a cell surface receptor. Mutations of TACSTD2 result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.